Monosodium urate deposition arthropathy part II: Treatment and long-term management of patients with gout

Advanced Studies in Medicine

Volumn 5, Issue 4, 2005, Pages 183-194

  Wortmann, Robert L ^a,d   Schumacher Jr , H Ralph ^b,c   Lewis Jr , C S ^a  

^a University of Oklahoma Tulsa College of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BENZBROMARONE; CELECOXIB; CIMETIDINE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; DICLOFENAC; ERYTHROMYCIN; ETORICOXIB; FEBUXOSTAT; INDOMETACIN; KETOROLAC; MERCAPTOPURINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROBENECID; STEROID; TOLBUTAMIDE; TRIAMCINOLONE ACETONIDE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL CRAMP; ARTHROPATHY; BONE MARROW SUPPRESSION; COHORT ANALYSIS; CONFUSION; DIARRHEA; DISEASE COURSE; DISEASE PREDISPOSITION; DYSPEPSIA; EOSINOPHILIA; EXFOLIATIVE DERMATITIS; FEVER; GOUT; HEADACHE; HEPATITIS; HUMAN; HYPERSENSITIVITY; HYPERURICEMIA; INCIDENCE; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEUKOCYTOSIS; LIFESTYLE; LIVER NECROSIS; NEPHROTIC SYNDROME; PREVALENCE; RASH; REVIEW; SEIZURE; STEVENS JOHNSON SYNDROME; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS; URIC ACID STONE; VOMITING;

EID: 18644368739     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Kim KY, Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25:1593-1617.
2. Chen LX, Schumacher HR. Gout and gout mimickers: 20 clinical pearls. J Musculoskel Med. 2003;20:254-258.
3. Gorter KJ, Tan G, Verstappen WHJM, et al. NHG Practice Guideline 'Gout'. Available at: http://nhg.artsennet.nl/upload/ 104/guidelines2/E72.htm. Accessed January 7, 2005.
4. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647-1655.
5. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937-943.
6. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-crt. Drugs. 2004;64:2399-2416.
7. Becker MA, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology, Volume 2. 15th ed. Philadelphia, Po: Lippincott Williams & Wilkins; 2005:2303-2339.
8. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29:331-334.
9. Dorwart BB, Hansell JR, Schumacher HR Jr. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum. 1974;17:563-571.
10. Rott KT, Agudelo CA. Gout. JAMA. 2003;289:2857-2860.
11. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for prophylactic use of colchicine in gout. J Rheumatol. 1991; 18:264-269.
12. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.
13. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004;50:2400-2414.
14. St-Onge MP, Keller KL, Heymsfield SB. Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. Am J Clin Nutr. 2003;78:1068-1073.
15. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103-108.
16. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
17. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study, Lancet. 2004;363:1277-1281.
18. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-1103.
19. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451.
20. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539-543.
21. Kerr LD. Inflammatory arthritis in the elderly. Mt Sinai J Med. 2003;70:23-26.
22. Schlesinger N, Schumacher HR Jr. Update on gout. Arthritis Rheum. 2002;47:563-565.
23. Fam AG. Strategies and controversies in the treatment of gout and hyperuricemia. Baillieres Clin Rheumotol. 1990;42:177-192.
24. Fam AG. Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998;13:229-243.
25. Fam AG. "Problem" gout: clinical challenges, effective solutions. J Musculoskelet Med. 1997;14:63-77.
26. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomized double blind trial of etoricoxib and indometacin in treatment of acute goufy arthritis. BMJ. 2002;324:1488-1492.
27. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis. 1991;50:263-266.
28. Burack DA, Griffin BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92:141-146.
29. George T, Mandell BF. Gout in the transplant patients. J Clin Rheumatol. 1995;1:328-334.
30. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59:1799-1806.
31. Fendrick AM, Garabedian-Ruffalo SM. A clinician's guide to the selection of NSAID therapy. Pharm Ther. 2002;27:579-582.
32. Fam AG. Managing problem gout. Ann Acad Med Singapore, 1998;27:93-99.
33. Molad Y. Update on colchicine and its mechanism of action Curr Rheumatol Rep. 2002;4:252-256.
34. Hartung EF. History of the use of colchicium and related medicaments in gout with suggestions for further research. Ann Rheum Dis. 1954;13:190-200.
35. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-304.
36. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48-59.
37. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy - classical indications and new therapeutic uses. Eur J Med Res. 2001;6:150-160.
38. Chattopadhyay I, Shetty HG, Routledge PA, Jeffery J. Colchicine induced rhabdomyolysis. Postgrad Med J. 2001;77:191-192.
39. Gershman K, McCullough DM. The little black book of geriatrics. Malden, Mass: Blackwell Science; 1998:217-220.
40. Meiner SE. Gouty arthritis: not just a big toe problem. Geriatr Nurs. 2001;22:132-134.
41. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol. 2001;13:240-244.
42. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-979.
43. Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol. 1999;11:441-445.
44. Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995;21:151-161.
45. Wallace SL, Singer JZ, Review: systemic toxicity associated with the intravenous administration of colchicines - guidelines for use. J Rheumatol. 1988;15:495-499.
46. Evans TI, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol. 1996;23:143-148.
47. Alloway JA, Moriarty MJ, Hoogland YT, Noshel DJ. Comparison of triamcinolone acetonide with indomethocin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20:111-113.
48. Groff GD, Franck WA, Raddotz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19:329-336.
49. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988;33:803-805.
50. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21:1325-1327.
51. Fam AG. Current therapy of acute microcrystalline arthritis and the role of corticosteroids. J Clin Rheumatol. 1997;3:35-40.
52. Ritter J, Kerr LD, Valeriano-Morcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994; 21:696-699.
53. Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002;46:2765-2775.
54. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14:445-460.
55. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989;16:1246-1248.
56. Van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long term antihyperuricemic therapy in tophaceous gout. J Rheumatol. 1993;20:1383-1385.
57. McCarty DJ. Gout without hyperuricemia. JAMA. 1994;271:302-303.
58. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep. 2001;3:29-35.
59. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28:577-580.
60. Chen LX, Schumacher HR. Diagnosis and management of gout. J Sci Commun. 2003;10:337-342.
61. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325.
62. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol. 1995;22:1621-1623.
63. Bills S, Isenberg D. Controlling hyperuricemia in general practice. Practitioner. 1999;243:886-891.
64. Kot TV, Day RO, Brooks PM. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust. 1993;159:182-184.
65. Schumacher HR, Smolyo AP, Tse RL, Maurer K. Arthritis associated with apatite crystals. Ann Intern Med. 1977;87:411-416.
66. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med. 1996;100:465-525.
67. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988;14:441-457.
68. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-286.
69. Palella TD, Kelley WN. An approach to hyperuricemia and gout. Geriatrics. 1984;39:89-102.
70. Simkin PA. Management of gout. Ann Intern Med. 1979;90:812-816.
71. Ferroz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22:908-914.
72. Thompson GR, Duff IF, Robinson WD, Mikkelsen WM, Golindez H. Long term uricosuric therapy in gout. Arthritis Rheum. 1962;5:384-396.
73. van Doornum S, Ryan P. Clinical manifestations of gout and their monagement. Med J Aust. 2000;172:493-497.
74. Perez-Ruiz F, Calabozo M, Fernandez-Lopez J, et al. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study. J Clin Rheumatol. 1999;5:49-55.
75. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol. 2002;17:625-626.
76. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia [published erratum in Kidney Int. 2000;57:370]. Kidney Int. 1999;56:1879-1885.
77. Wurzner G, Gerster JC, Chiolero A, et.al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19:1855-1860.
78. Softer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
79. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation. 1998;66:268-271.
80. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28:2294-2297.
81. Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9:215-218.
82. Perkins P, Jones AC. Gout. Ann Rheum Dis. 1999;58:611-616.
83. Louthrenoo W, Kasitanon N, Wichainun R, Sukitawut W. Effect of minidose ospirin on renal function and renal uric acid handling in healthy young adults. J Clin Rheumatol. 2002;8:299-304.
84. Danaher PJ, Bryant LR, Alloway JA, Harris MD. The effect of low dose aspirin on serum urate levels and urinary excretion in patients receiving probenedd for gouty arthritis. Arthritis Rheum. 1999;42:S173-S177.
85. Harris M, Bryant LR, Danaher P, Alloway JA. Effect of low dose daily aspirin an serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol. 2000;27:2873-2876.
86. Murrell GA, Ropeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacakinet. 1986;11:343-353.
87. Lackard O Jr, Harmon C, Nolph K, Irvin K. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med. 1976;85:333-335.
88. Honde KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
89. Simmonds HA, Cameron JS, Morris GS, Davies PM. Allopurinol in renal failure and tumor lysis syndrome. Clin Chim Acta. 1986;160:189-195.
90. Yue TF, Gutman AB. Effect of allopurinol [4 hydroxypyrazolo-(3,4-d) pyrimidine] on serum and urinary uric acid in primary and secondary gout. Am J Med. 1964;37:885-898.
91. Stamp L, Sharples K, Gow P, Raill B. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30:567-572.
92. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol. 1988;26:423-438.
93. Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxypurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol. 1990;39:419-421.
94. Fox IH. Antihyperuricemic drugs. In: Kelley WN, Harris ED Jr, Ruddy S, Siedge CB, eds. Textbook of Rheumatology. Vol. 2. Philadelphia, Pa: WB Sounders Co; 1993:822.
95. Kamoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993;250:455-460.
96. Benito-Leon J, Porta-Etessam J. Guillain-Barre syndrome and allopurinol-induced hypersensitivity. Eur Neurol. 2001; 45:186-187.
97. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992;93:299-302.
98. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-87.
99. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-343.
100. Vazquez-Mellado J, Vazquez SG, Barrientos JC, Rios VG, Burgos-Vargas R, Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout. J Clin Rheumatol. 2000;6:266-268.
101. Monev SD. How should hyperuricemia be treated in a patient with allopurinol hypersensitivity? Cleve Clin J Med. 2001;68:597-598.
102. O'Duffy JD. Oxypurinol therapy in allopurinol-sensitive patients [abstract]. Arthritis Rheum. 1993;36:S159.
103. Earl JM, Saavedra M. Oxypurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983;28:147-148.
104. Dunne SM, Fam AG, Iazzetta J. Efficacy and safety of desensitization to allopurinol following cutaneous reactions [abstract]. Arthritis Rheum. 1998;41:S151.
105. Hoffman IA. My gout and allopurinol desensitization. J Clin Rheum. 2002;8:354-357.
106. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
107. Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity ond potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 1999;104:307-319.
108. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855.
109. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993;241:183-188.
110. Kamatani N, Fujimori S, Hada T, et al. Febuxastat, a novel non-purine selective inhibitor of xonthine oxidase, in an albpurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia. Am Coll Rheum. 2004: Abstract 804/184.
111. Kamatani N, Fujimori S, Hada T, et al. Febuxostat, a novel non-purine selective inhibitor af xanthine oxidose, in a phose III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia. Am Coll Rheum 2004:Abstract 805/185.
112. Schumacher HR, Wortmann R, Becker MA, et al. A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Am Coll Rheum. 2004; Abstract 800/180.
113. Terkeltaub R. Pathogenesis and treatment of crystal-induced inflammation. In: Koopman WJ, ed. Arthritis and Allied Conditions. 14fh ed. Philadelphia, Pa: Lippincott, Williams and Wiikins; 2001:2329-2347.